Skip to main content
Clinical Trials/NCT06601647
NCT06601647
Not yet recruiting
Not Applicable

A Prospective, Randomized, Double-blind Study: Effects of Different Adjuvants Combined with Ropivacaine in Interscalene Block on Postoperative Outcomes After Arthroscopic Rotator Cuff Repair

Taipei Veterans General Hospital, Taiwan1 site in 1 country120 target enrollmentOctober 1, 2024
ConditionsAnesthesia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia
Sponsor
Taipei Veterans General Hospital, Taiwan
Enrollment
120
Locations
1
Primary Endpoint
postoperative pain evaluated by NRS
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The pain after shoulder rotator cuff repair surgery is severe due to the inflammatory reaction of tendon repair. Severe pain will reduce the patient's shoulder range of motion and delay functional recovery. The use of powerful analgesics for pain relief may also increase the chance of opiate analgesic-related side effects. Brachial plexus block with local anesthetic is widely used for pain control at the acute stage after shoulder arthroscopic surgery, but the maintenance time is often limited. Ropivacaine is a local anesthetic commonly used for brachial plexus block, and its half-life time is 11.8 hours. Clinical studies showed that using ropivacaine plus adjuvants such as dexamethasone or dexmedetomidine for brachial plexus block significantly extended the block duration, reduced postoperative pain, and reduced the use of opiate analgesics. However, the safest and most effective combination of local anesthetics remains unresolved.

This trial aims to evaluate and compare the effects of brachial plexus block using dexamethasone and dexmedetomidine combined with ropivacaine on postoperative pain control and functional recovery after arthroscopic rotator cuff repair surgery.

Detailed Description

Shoulder joint surgery is an orthopedic surgery recognized to cause severe postoperative pain. The pain after shoulder rotator cuff repair surgery is severer than other shoulder joint surgeries due to the inflammatory reaction of tendon repair. Severe pain will reduce the patient's shoulder range of motion and delay postoperative functional recovery, and the use of powerful analgesics for pain relief may also increase the chance of side effects related to opiate analgesics. Therefore, postoperative pain control has become an important clinical issue. Brachial plexus block with local anesthetic is widely used for pain control at the acute stage after shoulder arthroscopic surgery, but the maintenance time is often limited. Ropivacaine is a local anesthetic commonly used for brachial plexus block, and its half-life time is 11.8 hours. Clinical studies showed that using ropivacaine plus adjuvants such as dexamethasone or dexmedetomidine to perform brachial plexus block significantly extended the block duration, reduced postoperative pain, and reduced the use of opiate analgesics. Brachial plexus block with low-dose dexmedetomidine plus ropicavaine significantly prolonged analgesia by 4 hours (14 hours vs. 10 hours) compared to ropicavaine alone, and reduced the dose of opiate analgesias in the first 24 hours after surgery. Compared to ropicavaine only, low-dose dexamethasone plus ropivacaine effectively extended the analgesic duration by 8 hours (19.7 hours vs. 11.8 hours) and reduced the dose of opioid analgesics within 36 hours after surgery (6.5mg versus 2mg). Meanwhile, continuous administration of ropicavaine through a catheter for brachial plexus block can maintain effective analgesia. However, the safest and most effective combination of local anesthetics remains unresolved. This trial aims to evaluate and compare the effects of brachial plexus block using adjuvants dexamethasone and dexmedetomidine combined with ropivacaine on postoperative pain control and functional recovery following arthroscopic rotator cuff repair surgery. Specifically, we will examine the effect of dexamethasone or dexmedetomidine alone, and in combination, on the duration of the analgesic effect of ropivacaine.

Registry
clinicaltrials.gov
Start Date
October 1, 2024
End Date
September 30, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hsin-Yi Wang

Doctor

Taipei Veterans General Hospital, Taiwan

Eligibility Criteria

Inclusion Criteria

  • age\>=20 years
  • scheduled to anthroscopic rotator cuff repair at VGH, Taipei

Exclusion Criteria

  • with central or peripheral neurological disease
  • refuse to sign informed consent
  • ASA score \>=4
  • blood oxygen saturation concentration \<90% when without using oxygen
  • emergent surgery
  • unstable vital signs (ie, use of vasopressors or inotropes)
  • nasal mucosa damage or a history of nasal or skull base surgery
  • not suitable for regional anesthesia (ie, abnormal coagulation function, taking anticoagulants)

Outcomes

Primary Outcomes

postoperative pain evaluated by NRS

Time Frame: postoperative 1hr (hour), 6hrs, 12hrs, 18hrs, 24hrs, 36hrs, 48hr; 3days , 7days, 14days, 30days, 60days, 180days

pain level by Numeric rating scale( 11 points ranging from 0 to 10; higher scores mean a worse outcome)

Study Sites (1)

Loading locations...

Similar Trials